My short answer on your question is that all changes are minor and have no impact on the the projections, those are clarifications.
If the extension study is a part of the original dose escallation or not will not have an impact on PF2 as the pivotal study is a randomised study. Because it is randomised it is a stand alone study.
Anyway, my clear understanding of this is that the extension study is an expansion of the original dose escalation, and that it is defined as dose escalation.
Thanks Snøffelen,
and yes PW confirmed that patients from extension study will not participate in PF2 as this will have to be randomized, this was during q1 presentation in March webcast QA session, during the same QA session there was an interesting discussion on criteria for pricing single vs multiple treatments including comments from jonas einarsson, recommend investors to listen to it
PCI Biotech: Invitation to first half year 2018 presentation
Oslo, 23 August 2018 - PCI Biotech invites to a presentation of the company’s second quarter and first half year 2018 report on Thursday 30 August 2018 at Oslo Cancer Cluster Innovation Park.
Time: Thursday August 30, 08:30am . 09:30am CEST (local time).
Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, OsloThe presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to post@pcibiotech.com.
The presentation will also be a live audiocast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the audiocast console.
The interim report and the presentation will be available on www.newsweb.no and on the company’s webpage, www.pcibiotech.com from 07:30am (CEST) on 30 August 2018.
For further information, please contact:
Ronny Skuggedal, CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
Nyheten er levert av GlobeNewswire.
http://www.netfonds.no/quotes/release.php?id=20180823.GlobeNewswire.GNW1000096625-en
Does anyone think we might actually get safety for the extension study in the H1 presentation. PCI have a bit of a habit of slipping out some info in quarterly presentations. If I remember correctly, response at the single lesion level for cohort 3 and 4 was released via a quarterly presentation.
I belive we do, that and some other precious intel ! 
Tweet fra Radforsk idag;
Vi hører fra lyttere av podkasten #Radium at dere har abstinenser etter nye, “vanlige” episoder. Det har vi og, så neste uke starter vi innspillingen fra studioet vårt i @OsloCancer Innovasjonspark m nye dyktige Ullern-elever som produsenter. Ny innspillingsdag blir onsdag 
Jeg har ikke noe stort håp om oppdateringer bortsett fra oppdaterte OS tall fra de siste gjenlevende. Disse tallene har aldri vært kursdrivende så vi kommer nok til å vake rundt femtilappen til vi får pf2 og finansiering i orden.
Men det hadde selvsagt vært fett med resultatet fra gjentakende 
Pci opportunity in veterinary medicine
The list seems endless regarding usage of PCI 
Pci is mentioned here in this q-1 2018 FCF life science monitor from Germany, quite a good read as it maps biotech industry in Europe and also helps screening potential investment across the continent.
Pci biotech is mentioned under therapeutic-small from page 29. And it states that expected profibility > 2021
Stock DZ,
your latest reference opens a vision of another shareholder structure some weeks after the big decisive questions are settled. The majority of the top50 (and I guess even more so when it comes to top100) are private investors with limited resources to defend their share of the company in the long run.
… which means that the ones from the “old family” (the settlers) could end up disgustingly rich even if they only could put aside 10k or more.
This is fcf Life Science monitor Q-2 2018, PCI Biotech profitibility updated to >2022
FCF-Life-Science-Monitor-Q2-2018.pdf (5,8 MB)
Off subject
From the FCF q2 2018 report you can also see some Norges Bank Investment companies:
Pharnext S.A, (France) Norges bank rank #2, ownership 2%
Virbac S.A, (France) Norges bank rank #2, ownership 2%
Drägerwerk AG & Co. KGaA, (Germany) Norges bank rank #2, ownership 4%
Guerbet S.A, (France) Norges bank rank #2, ownership 3%
Just one last input on Norges Bank Investment Management in Pharmaceuticals (and we close this subject), as per 31/12/2016, the fund was investing in 687 Pharmaceutical companies with more than 554 billion nok (67,7 billion usd) Here is the link to find the list, choose industry and select healthcare (you can play and rank the investments by value, country …etc)
also below is a snap shot of their biggest investment. Imagine if just a small fraction of this money is going to Norway biotech industry 
since as per 31/12/2016 the fund had 0,000 nok invested in Norwegian biotech industry
https://www.nbim.no/en/the-fund/holdings/holdings-as-31.12.2016/?fullsize=true
Alt på grunn av dogmet om internasjonal risikospredning. Sentrumseiendommer og hele gater - i bl.a. London og Berlin - går greit innenfor investeringspolitikken, men sjøl om den norske staten er fullinvestert i petroleum, nekter den å sette ei krone på en av de næringene som har framtida for seg i et land med sterk grunnforskning og masse interessant preklinisk arbeid.
Stupid if you ask me.
Det er folketrygdfondet som investerer i Norge. Og jeg ser med blandede følelser på inntreden fra dem.
Jo, det er gjeldende policy / arbeidsdeling. Du har gjerne sjekka det; har Folketrygdfondet investert noe som helst i norsk biotek- i så fall i hvilke selskap? Nattopharma og Biotech Pharmacon? Nå var jeg slem 
Tror jeg googlet det engang. De driver vel mest med edb.
Folketrygdfondet er vel 2 største aksjonær i Nano hvis jeg ikke tar feil?
@Savepig dette har vel du kontroll på, de investerer vel der de har troa.
Edit: FTF har over 2,7 millioner aksjer i Nano, så noe biotek er de inne i ja.
